[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)]
Apr 2004 - Pneumologie; 58(4):0934-8387 [PMID:15098157]
[Bruns I] [Kohlmann T] [Wiedemann GJ] [Bakhshandeh A]

A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma.
May 2003 - Oncology; 64(4):0030-2414 [PMID:12759526]
[Westermann AM] [Wiedemann GJ] [Jager E] [Jager D] [Katschinski DM] [Knuth A] [Vörde Sive Vörding PZ] [Van Dijk JD] [Finet J] [Neumann A] [Longo W] [Bakhshandeh A] [Tiggelaar CL] [Gillis W] [Bailey H] [Peters SO] [Robins HI]

Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
Mar 2003 - Lung Cancer; 39(3):0169-5002 [PMID:12609573]
[Bakhshandeh A] [Bruns I] [Traynor A] [Robins HI] [Eberhardt K] [Demedts A] [Kaukel E] [Koschel G] [Gatzemeier U] [Kohlmann T] [Dalhoff K] [Ehlers EM] [Gruber Y] [Zumschlinge R] [Hegewisch-Becker S] [Peters SO] [Wiedemann GJ]

[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma]
Apr 2000 - Dtsch. Med. Wochenschr.; 125(11):0012-0472 [PMID:10761473]
[Bakhshandeh A] [Bruns I] [Eberhardt K] [Wiedemann GJ]

Systemic hyperthermia and ICE chemotherapy for sarcoma patients: rationale and clinical status.
Oct 1997 - Anticancer Res.; 17(4B):0250-7005 [PMID:9329558]
[Wiedemann GJ] [Robins HI] [Katschinski DM] [Mentzel M] [D'Oleire F] [Kutz M] [Wagner T]